Evaluation of the Effectiveness of Meloxicam in the Treatment of Patients with Rheumatoid Arthritis in Older Age Groups

Simple item page
dc.creatorSh., Tilloeva Sh.
dc.creatorA., Nabieva D.
dc.date2022-04-23
dc.date.accessioned2023-08-21T04:48:42Z
dc.date.available2023-08-21T04:48:42Z
dc.descriptionThe article presents the results of a study of the clinical efficacy and tolerability of a new generation of non-steroidal anti-inflammatory drugs (NSAIDs) meloxicam 10 mg cyclooxygenase inhibitors (COX-2 inhibitor) in the treatment of rheumatoid arthritis in patients of older age groups. In 35 patients with rheumatoid arthritis (RA) of both sexes aged 45-65 years, an open clinical study of the action of meloxicam was performed. During the treatment period, basic therapy, drugs that improve heart function, diuretics and antiplatelet agents were prescribed. Controlled clinical and laboratory parameters were assessed before the inclusion of patients in the study and after the end of therapy.en-US
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.identifierhttps://emjms.academicjournal.io/index.php/emjms/article/view/289
dc.identifier.urihttp://dspace.umsida.ac.id/handle/123456789/8044
dc.languageeng
dc.publisherAcademic Journal Incorporationsen-US
dc.relationhttps://emjms.academicjournal.io/index.php/emjms/article/view/289/311
dc.relationhttps://emjms.academicjournal.io/index.php/emjms/article/view/289/343
dc.sourceEuropean Multidisciplinary Journal of Modern Science; Vol. 5 (2022): European Multidisciplinary Journal of Modern Science; 407-411en-US
dc.source2750-6274
dc.subjectrheumatoid arthritisen-US
dc.subjectNSAIDsen-US
dc.subjectcyclooxygenase (COX-2) inhibitorsen-US
dc.titleEvaluation of the Effectiveness of Meloxicam in the Treatment of Patients with Rheumatoid Arthritis in Older Age Groupsen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US
Files
Collections
European Multidisciplinary Journal of Modern Science (ISSN 2750-6274)